Citron Kinase, a mitotic kinase with increasing significance in cancer Authors: Elodie Mitri, Caroline Callot, Anastassia Hatzoglou, Arnaud Besson Published: 2026 ABSTRACT ABSTRACTCell division is an essential process required to maintain homeostasis. It must be tightly coordinated to allow the faithful transmission of the genetic material, and its regulation involves numerous partners. While some of them are well-characterized (e.g. Cyclin-Dependent Kinases, Aurora Kinases, …), others are still poorly understood. Citron Kinase (CitK) plays key roles during mitosis and cytokinesis, although its functions remain to be fully elucidated. In addition, its roles are not restricted to cytokinesis, and CitK also comes into play at earlier stages of cell division. Furthermore, emerging evidence suggests a role for CitK during tumorigenesis. Several studies have pointed to the potential of targeting CitK in the context of cancer treatment and hopefully this will bring attention to this largely understudied kinase. This review focuses on the different functions of Citron Kinase throughout the cell cycle to highlight its importance during cell division as well as its significance in cancer and its potential as a target for cancer therapy.KEYWORDS: Cell cycle, mitotic kinases, cytokinesis, Citron Kinase, cancer Introduction Cell division is among the most fundamental process in all living organisms, ensuring their growth and reproduction. This division can take very different forms and modalities depending on the species. In multicellular organisms, additional control mechanisms exist to ensure the maintenance of tissue shape and size. The cell division cycle is divided into two main phases: interphase (G0/G1, S, and G2 phases) and mitosis (M phase) [1,2]. During vegetative cell division, mitosis allows the proper segregation of the nuclear material, especially chromosomes, to give rise to genetically identical daughter cells. Cell division is complete only after the completion of cytokinesis, which allows the segregation of the cytoplasmic material and organelles and the physical separation of daughter cells during abscission. Cell division is an exquisitely complex process accompanied by dramatic rearrangement of virtually all cellular structures and therefore must be tightly regulated. Many proteins are implicated in this regulation, including Microtubules-Associated Proteins (MAPs), kinesins, dyneins, as well as kinases and phosphatases. Kinases play a key role during this process; indeed, phosphorylations affect the behavior and activity of a large numbers of proteins to ensure the progression and proper regulation of mitosis [3]. Importantly, dysregulation of mitotic kinases can impair the accurate segregation of chromosomes or cause cytokinesis defects, causing aneuploidy and genetic instability, thereby promoting tumorigenesis [4,5]. Mitotic kinases are a large family that can be divided into different subgroups, including cyclin‑dependent kinases (CDKs), polo-like kinases (PLKs), Aurora kinases, NIMA-related kinase (NEKs) and checkpoint kinases (Figure 1A), as well as individual kinases such as Greatwall kinase, Haspin or Citron Kinase (CitK, also known as Citron Rho-interacting serine/threonine kinase (CRIK)) [1]. Since dysregulation of mitotic kinases can lead to cancer, most have been extensively studied and their functions well-characterized, and inhibiting these kinases can be a therapeutic option in some cases [1,2,6–9]. Nevertheless, several mitotic kinases such as CitK remain understudied despite their crucial involvement in regulating cell division. The main cell cycle kinases acting throughout the cell cycle. CitK was initially described with a restricted function in cytokinesis, but more recent studies have also identified roles in earlier steps of mitosis as well as in interphase [10–18] (Figure 1B). These different functions are made possible by diverse localizations adopted by CitK throughout the cell cycle (Figure 1B). These specific localizations involve numerous partners and a fine-tuned regulation. Importantly, CitK has been involved in human diseases such as cancers. However, there are still many unresolved questions regarding this specific kinase. Here, we will discuss the roles of CitK throughout the cell cycle (see also D’Avino, 2017 [19]), give an overview of its more recently described functions beyond cytokinesis, and highlight its importance in the context of cancer, as increasing evidence suggests that CitK could represent a potential target in cancerology, warranting further study of this understudied kinase. A. Involvement of the main cell cycle kinases families in the different phases of the cell cycle, including Citron Kinase (CitK). Genome is represented in blue and red, centrioles in green circles and microtubules as green lines. Modified from Malumbres, 2011 [1]. B. Localizations (red) and functions (black) of CitK during the cell cycle. Created using biorender.com. Citron Kinase: an overview of this complex Kinase Citron kinase Citron Kinase was identified in 1995 as a Rho-GTPases interacting protein and was found to regulate cytokinesis, playing a critical role in maintaining midbody architecture and stability [11–13,20]. Without CitK, cells undergo abnormal cytokinesis and eventually fuse together due to reopening of the intercellular bridge, leading to the formation of multinucleated or polyploid cells [16,21]. Furthermore, the function of CitK is not restricted to cytokinesis, and it appears to be involved in the DNA damage response in interphase and in the early phases of mitosis (Figure 1B and see below). All of these functions will be described in more details hereafter. CitK is a large protein of 2027 amino acids (human canonical isoform) with a predicted molecular weight of 231 kDa, containing an N-terminal kinase domain followed by several domains that mostly mediate protein/protein and protein/lipid interactions (Figure 2A). CitK orthologs are found in all vertebrates, as well as in Drosophila and C. elegans. In those species, CitK is also a very large protein (1854 amino acids in Drosophila and 1286 amino acids in C. elegans). The three-dimensional structure of CitK is still unknown; nevertheless, analysis of its amino acid sequence using IUPred2A [22] revealed that it contains several intrinsically disordered regions located within the coiled-coil and PDZ domains (Figure 2B). The structural plasticity of these disordered regions confers the capacity to interact with a wide variety of protein partners (see below) [23], and this characteristic perfectly illustrates the dual functionality of CitK as a kinase and as a scaffold protein, which are both key for its function. Indeed, CitK interacts with many proteins, and some interaction domains have been mapped on CitK (Figure 3). During cytokinesis, CitK interacts both with cell cortex components such as RhoA [14] or Anillin [16] and with central spindle components such as the Chromosomal Passenger Complex (CPC, including Aurora B, Borealin and Inner Centromeric Protein [INCENP]) [12], Kinesin family member 14 (KIF14) [24] or Mitotic kinesin-like protein 1 (MKLP1/KIF23) [11]. CitK can also directly interact with membrane phospholipids through its Pleckstrin Homology (PH) and C1 domains. In this way, CitK allows the proper sequential arrangement of cytokinesis regulators at the cytokinetic contractile ring and at the midbody and contributes to anchoring the cell cortex and the central spindle, thus ensuring the stability of the intercellular bridge, so that cytokinesis proceeds normally. Domain structure of CitK and prediction of intrinsically disordered regions. (A). Representation of the different domains of CitK. The N-terminal half of CitK is composed of the serine/threonine kinase domain (orange) and a coiled-coil domain (gray). This domain contains the Rho Interaction Domain (RID; red), Homology Region 1 (HR1; red) and Rho Binding Domain (RBD; red). The C-terminal part contains a C1 (Zinc-Finger) domain (C1; blue), a Pleckstrin Homology domain (PH; yellow), a Citron-Nick1 Homology domain (CNH; green), a proline-rich region (light blue) and a PDZ domain (light yellow). (B). Prediction of intrinsically disordered domains within the CitK sequence using IUPred2A [22]. The gray and yellow rectangles, corresponding to the coiled-coil and PDZ domains, represent the predicted intrinsically disordered regions. Mapping of the interactions between CitK and its known partners. The different CitK partners listed on this figure appear right below the domain they interact with. Known partners for which the interaction domains have not been mapped yet are listed on the left as “other interactors.” The references describing each interaction are indicated beside each CitK partner [33–37]. Abbreviations used: Inner Centromere Protein (INCENP); Kinesin Family Member 14 (KIF14); Mitotic Kinesin-Like Protein 1 (MKLP1); Histone Deacetylase 6 (HDAC6); Rho-Associated Kinase II (ROCK II); myosin Phosphatase-Rho interacting protein (p116-RIP); Lim-Kinase (LIMK); Yes-Associated Protein (YAP); Disc Large 5 (Dlg5); Post-synaptic Density protein 95 (PSD-95); Ran binding Protein M (RanBPM); Abnormal Spindle-like Microcephaly-associated (ASPM); Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs); Ephrin type-B receptor 2 (EphB2); Protein Required for Cytokinesis 1 (PRC1). Evidence indicates that CitK can potentially interact with many more partners. Indeed, two interactomes have been published, based on CitK immunoprecipitation followed by mass spectrometry identification of the partners pulled-down [12,25]. Our team also determined the CitK interactome by a different approach using a V5-tagged CitK produced in HEK 293 cells to screen high-density protein arrays with over 9000 proteins spotted (ProtoArray V5.1, Invitrogen). Using this approach, 260 binding partners were identified that presumably bind CitK via direct interactions (Supplementary Table 1). First, our interactome confirms the interaction of CitK with a number of mitotic kinases, including AURKA and -B kinases, NEK6 and −7 and PLK1. CitK also potentially interacts with regulators of cytoskeleton dynamics, such as MAP7, cortactin and KIF2A, which are involved in cytokinesis, supporting published data where CitK appears important to maintain F-actin at the secondary ingression sites during abscission [26–29]. CitK also indirectly plays a role in microtubule stability at the midbody by modulating the phosphorylation of tubulin β-III (TUBB3) by Casein Kinase 2α (CK2α) [30]. The interactome also revealed a potential interaction with CHK2, and other proteins involved in the DNA damage response, which is consistent with the previously reported role for CitK in this process [17,18,31,32]. Gene ontology analysis of the gene identified in the interactome (Supplementary Table 2) confirms the involvement of CitK in the mitotic process, DNA repair or signal transduction, but strikingly points toward yet unknown roles of CitK in RNA processing, splicing and metabolism. Thus, the number and diversity of these interactors strengthen the idea that CitK has a complex role and that its involvement in regulating various cellular functions remains to be investigated. Regarding its kinase activity, CitK is a serine/threonine kinase of the AGC family. Only one substrate of CitK has been identified so far: INCENP, a component of the CPC [12]. The identification of other CitK substrates will be instrumental to better understand its function. However, the catalytic function is not sufficient for CitK to fully exert its role, since CitK-KD (kinase dead) only partially rescues the multinucleation phenotype caused by its depletion (using siRNA) in both human and Drosophila [10,14]. This information highlights the requirement of both its kinase activity and its scaffolding properties to allow proper cytokinesis, which appears to be conserved across species. Citron N CIT, the gene encoding CitK, also produces an isoform lacking the kinase domain (amino acids 1–467) named Citron-N (CitN, for Neural or Non-kinase) [13]. Although most evidence for this isoform was observed in mammals, the CitN isoform seems conserved across classes, since a recent article in C. elegans described a role for a CitN ortholog [38]. While CitK is expressed in all proliferating cells, CitN expression is restricted to postmitotic cells in the central nervous system, with the highest levels in differentiated neurons [39–41]. Recently, CitN was involved in controlling microtubule dynamics in post-mitotic neurons [38]. Indeed, the CitN ortholog in C. elegans acts as a key player in regulating neuronal microtubules polarity and stability. This process involves Abnormal Spindle-like Microcephaly-associated (ASPM), probably acting in the same pathway since no additive effects were observed in double‑mutant animals [38]. Finally, both proteins were found to control microtubule dynamics by binding to microtubules plus-ends, although the exact mechanism is still unclear, but their localization at this specific site was independent of each other. In primary neural cells, CitN controls cytoskeleton dynamics by acting as a scaffold for ROCK2 and Profilin-2 to mediate Rho-dependent actin-polymerization on Golgi membranes, ensuring the maintenance of this organelle [42]. CitN is also important for the maturation and maintenance of dendritic spines in neurons [43]. Functions of CitK throughout the cell cycle The localization of CitK changes throughout the cell cycle, revealing different functions. Cytoplasm As described above, the first evidence for a function during interphase was obtained with CitN. Although a link between CitK and the Golgi network has never been described, it is tempting to speculate that CitK may also be involved in this process, since CitK and CitN share the same protein–protein interaction domains and that the Rho-binding domain (RBD) and the C-terminal domain are key for this function [42]. CitK was recently involved in the regulation of DNA damage signaling in interphase [17,18]. Indeed, upon CitK depletion, cells accumulate DNA damages, and this was accompanied by an impairment of RAD51 recruitment to DNA damage sites in CitK-depleted cells [17]. The interaction between RAD51 and CitK was confirmed; however, CitK was never detected at damage sites, suggesting an indirect role [17]. A subsequent study described a role for CitK with another repair protein, BRCA1 [18]. As for RAD51, in the absence of CitK, BRCA1 is recruited less efficiently to DNA damage sites. While the link between CitK and RAD51 was not really understood, CitK-mediated recruitment of BRCA1 appears to be dependent on HDAC6 [18]. Indeed, CitK interacts with HDAC6 to prevent microtubule destabilization through de-acetylation, thereby promoting the efficient recruitment of BRCA1 in the nucleus [18]. The exact role of CitK in the DNA damage response is still unclear but appears to be indirect. However, this new role is in agreement with previous observations where CitK inhibition leads to accumulation of DNA damages [31,44–46], a phenotype that could be secondary to cytokinesis defects, but also be caused via the regulation of the DNA damage response by CitK. Finally, CitK was reported to participate in the regulation of the Hippo pathway by serving as a scaffold for both LATS2 and YAP [47]. When binding to LATS2, CitK prevents its activation by blocking LATS2 phosphorylation by MST1, which in turn allows the activation of YAP [47]. Although the physiological effect at the cellular level is still unclear at this point, it is possible that the regulation of LATS2/YAP signaling by CitK participates in the control of cytokinesis, as LATS2 knockout causes cytokinesis defects, polyploidy and multinucleation, and LATS2 was shown to regulate AuroraB activity during cytokinesis [48,49]. Thus, although the function of CitK has been solely described during mitosis for many years, recent evidence points toward an important function of the protein during interphase too. Spindle poles and astral microtubules After entry into mitosis, CitK is localized to the spindle poles through its interaction with ASPM [15]. At this specific location, CitK controls the nucleation of astral microtubules, as well as their length and orientation [15]. Those microtubules are particularly important to control mitotic spindle orientation [50]. In the central nervous system, mammalian Disc-large 5 (Dlg5) was found to be required in metaphase to polarize CitK to the ventricular zone surface in mitotic neural progenitors to ensure proper spindle orientation and cytokinesis [51]. Central spindle and cleavage furrow When the spindle is formed and stably oriented, CitK is recruited to the central spindle by the kinesin KIF14 and the microtubule-associated protein Protein Regulating Cytokinesis 1 (PRC1) [11,24,52,53]. Once sister chromatids are separated, the formation of the cleavage furrow begins, and at this stage, CitK relocalizes to the cell cortex. During constriction, CitK is found at the cleavage furrow, where it interacts with actin, myosin, RhoA and Anillin [10,16]. However, the exact mechanism that mediates the relocalization of CitK to the cleavage furrow is still unclear. It was initially described to be a RhoA-dependent mechanism [54], but this model was later challenged [10,14,16]. Indeed, the inactivation of RhoA does not affect the localization of CitK [16], and it appears more likely that CitK participates in maintaining RhoA and Anillin at the cleavage furrow [10,14,16]. More recently, a model was proposed in which RhoA recruits CitK at the cleavage furrow directly, and indirectly via Anillin [55]. The constriction of the contractile ring leads to the formation of the intercellular bridge, and CitK must be relocated at the midbody ring in late telophase, where it exerts its main known functions. Midbody ring The localization of CitK at the midbody ring is essential to organize and maintain the midbody structure, and the loss of CitK expression results in midbody disorganization and instability [11,12,56]. This specific role in maintaining midbody stability is mainly due to its ability to act as a scaffold protein (as discussed above and Figure 3) [19]. However, it is important to control the timing of CitK relocalization and of its interactions with its many different partners, both of which appear to be regulated by phosphorylation events on CitK. First, CitK is phosphorylated by CDK1 on S440 early in mitosis, and this is important for midbody formation and stability; this phosphorylation is then removed in anaphase [57]. In late anaphase/early telophase, CitK phosphorylates the CPC component INCENP; this phosphorylation allows the recruitment and activation of Aurora B (also a component of the CPC) [12,19]. In turn, Aurora B phosphorylates CitK on S699 [12,57]. These two phosphorylations (S440 and S699) within the coiled-coil domain dampen the interaction between CitK and MKLP1, KIF14 or Aurora B, probably to prevent a premature interaction between CitK and those partners and an early accumulation of CitK at the midbody [57]. Then, in late telophase, CitK must be transferred to the midbody ring. This transfer is mediated by KIF14 that interacts within the coiled-coil domain of CitK [11,14,24]. Once at the midbody, CitK forms a network by interacting with many partners. First, CitK maintains KIF14 and MKLP1 at the midbody ring [11]. The loss of CitK also alters the localization of PRC1 [11], and CitK directly interacts with PRC1 (Supplementary Figure 1). Both KIF14 and MKLP1 are also known to interact with PRC1 [24,58]. These four proteins are forming a network at the midbody ring that actively participate in its maintenance. Indeed, KIF14 loss also leads to midbody defects [11]. On the other hand, CitK still interacts with RhoA and Anillin to maintain an anchorage between the central spindle and the cell cortex [16]. The interaction between RhoA and CitK is modulated via phosphorylations on CitK by Src [59]. Finally, CitK also interacts with the CPC that is localized at the midbody arms. It seems obvious that CitK must be dephosphorylated at some point; however, the phosphatase involved and the timing of CitK dephosphorylation remain unclear at this point. Although some evidence suggests that PP1γ-MYPT1 could participate in dephosphorylating key midbody proteins such as MKLP1 in late cytokinesis [60]. In the absence of CitK, midbody organization is compromised, causing intracellular bridge instability and cytokinesis defects, leading to the formation of multinucleated or polyploid cells [16,21]. Polyploidy or aneuploidy can in turn promote genetic instability and cancer. Importance of Citron Kinase in the brain Genetic evidence indicates a strong requirement for CitK in the nervous system. Indeed, CitK knockout mice (but expressing normal levels of CitN) display microcephaly, neurological disorders and seizures [40]. This knockout also affects germinal cells in males, whereas other tissues appear to be unaffected [61]. However, why CitK depletion is detrimental in the brain and testis but not in other tissues is still an open question. Microcephaly is also observed in flathead rats that carry a spontaneous mutation in the Cit gene [62]. This mutation is a deletion in exon 1 leading to a premature stop codon that causes the specific elimination of the CitK protein without affecting expression of the CitN protein [62]. In those two models, neurogenic precursors massively die due to cytokinesis defects, underscoring the importance of CitK for neurogenic divisions [40,62–64]. In human, CitK deregulation is associated with microcephaly. Autosomal recessive primary microcephaly (MCPH) is a neurogenic mitotic disorder that leads to reduced brain size and developmental disorders caused by mutations in genes implicated in cell division [65,66]. Twenty‑nine genes causing MCPH have been identified so far, including CIT (MCPH17), as well as the CitK partners ASPM and KIF14. CitK mutations responsible for microcephaly are located within the kinase domain [67–70], highlighting the requirement for the catalytic activity of CitK, especially in the brain. The importance of its catalytic function for brain development has also been validated using organoids to model microcephaly [45]. More recently, an interaction between CitK and kinesin family member 1-binding protein (KIF1BP) has been described [25]. The recessive mutation of KIF1BP is responsible for the Goldberg–Shprintzen disease (GOSHS), a rare microcephaly syndrome [71]. The interaction between KIF1BP and CitK promotes midbody maturation and abscission [25]. Finally, as many microcephaly-causing proteins are involved in cell division, they have been proposed as potential targets to treat brain tumors, including CitK [72]. Indeed, CitK deregulation has been associated with cancers, and elevated CitK expression levels correlate with poor prognosis in several types of cancers [73–76]. Citron Kinase and cancer Genetic instability is a hallmark of cancer cells [77] and mutations or amplification of mitotic proteins are frequent. While no mutations have been described for CitK in cancer cells so far, its overexpression has been associated with poor prognosis [73–75]. Indeed, increasing evidence suggests a role for CitK in various types of cancers (Table 1). Table 1.CitK in cancer.Type of cancerClinical or genomic observationsPhenotypes reported in vitroPhenotypes reported in vivohepatocellular carcinoma [78]overexpression of CitK in tumoral tissue compared to non-tumoral tissuesshRNA in HCC cells: cytokinesis defects, G2/M arrest, decreased proliferation and survivalimplantation of HCC cells (sh-ctl or sh-CitK) in the flank of mice: decreased tumor sizeovarian carcinoma [79]bioinformatics analysis: high CitK expression correlates with longer time to progression breast cancer [80]bioinformatics analysis: elevated expression in tumors correlates with tumor grade stomach carcinoma [81]-bioinformatics analysis: elevated expression in gastric tumors-overexpression of CitK in cancer tissues compared to matched normal tissues breast cancer [73]overexpression of CitK in breast cancer samples compared to para-cancerous and normal tissuesshRNA in MDA-MB 231 and T-47D lines: reduced proliferation, cell death, G2/M arrest, decreased invasion and migrationimplantation of MDA-MB 231 cells (sh-ctle or sh-CitK) in the flank of mice: decreased tumor sizemedulloblastoma [31,32,44] -siRNA in DAOY or ONS-76 cells: apoptosis, DNA damages, G2/M arrest, multinucleation, decreased viability, senescence, reduced proliferation, sensitization to radiations and cisplatin−90 nM Lestaurtinib on ONS-76 and DAOY cells: reduced proliferation, cell cycle arrest, cell death, DNA damages-implantation of DAOY cells (inducible sh-CitK) in the flank of mice: reduced tumor growth and induction of senescence-CitK KO mice: DNA damages, apoptosis, reduced proliferation, decreased tumor size and improved mice survival-subcutaneous injection of ONS-76 cells + Lestaurtinib injection (100 nM in the tumor mass): nuclear abnormalities, apoptosis, DNA damages, decreased tumor sizemyeloma [82]-overexpression of CitK in myeloma samples compared to healthy donorsshRNA in OPM2 and MM.1s cells: multinucleation, G2/M arrestsubcutaneous injection of OPM2 cells (sh-ctle or sh-CitK) in the flank of mice: decreased tumor sizebladder [74,83,84]-bioinformatics analysis: high expression of CitK indicates poor prognosis, lower immune cell infiltration and insensivity to chemotherapy-higher expression of CitK in advanced cancer samples-siRNA on SW1710 and RT-4 lines: G2/M arrest, reduced proliferation-shRNA in 5637 and T24 cells: G2/M arrest, reduced proliferation, cell death, decreased expression of a specific circRNA, CDK1 and ROCK, increased expression of p53subcutaneous injection of T24 cells (sh-ctle or sh-CitK): decreased tumor sizeprostate cancer [75,85]Higher expression of CitK in prostate cancer samples-siRNA in prostate cancer cell lines: reduced proliferation−10 nM OTS-167 on prostate cancer cell lines: decreased viability, growth inhibition-inducible CitK in prostate cancer cells: increased proliferation-subcutaneous implantation of LNCaP cells (inducible CitK) in mice: decreased mice survival, presence of adenocarcinoma-subcutaneous implantation of R1-D567 cells (inducible shCitK) in mice: decreased tumor sizegastric cancer [86] CRISPRi using sgRNA against CIT: decreased proliferationsubcutaneous injection of YCC3 cells (sgRNA-ctle or sgRNA-CIT): decreased tumor sizeesophageal squamous cell carcinoma [87]bioinformatics analysis: higher CIT mRNA level in cancerous tissues compared to non-tumor tissuesshRNA in Eca-109 cell line: decreased proliferation, apoptosissubcutaneous injection of Eca-109 cells (sh-ctle or sh-CitK) in mice: decreased tumor size CitK in cancer. Clinical and genomic observations Several bioinformatics studies found elevated CitK expression in tumors compared to non-tumoral tissues, often accompanied by elevated levels of the CitK partners PRC1 and KIF14 [79–81]. For example, in breast carcinoma, its expression increased with tumor grade [80]. Inversely, in ovarian carcinoma, high CitK expression correlated with longer time to progression compared to tumors with low CitK levels [79]. However, these results are mostly correlative, and validations are needed to really conclude on the importance of CitK in these cancers. However, some clinical observations are consistent with the idea that CitK might have an importance in tumors. In 2011, a first study described elevated expression of CitK in hepatocellular carcinoma compared to adjacent non-tumor tissues [78]. Then, similar observations were made in different models (Table 1) such as breast, stomach or bladder cancers when comparing cancerous tissue to normal tissue [73,74,81]. Genetic studies in cancer cell lines Using cancer cell lines, different teams manipulated CitK levels using siRNA or shRNA to determine if CitK plays an important role in cancer cell proliferation. First, in hepatocellular carcinoma cells, CitK depletion with RNA interference induces cytokinesis defects accompanied by cell cycle arrest and decreased cell proliferation [78]. In breast cancer cells, CitK knockdown caused apoptosis, cell cycle arrest and cytokinesis defects, as expected, as well as a reduction of tumor cell invasive capacity [73]. This report provided the first implication of CitK in migration and invasion, consistent with its role in regulating cytoskeleton dynamics. In 2018, the involvement of CitK was described in medulloblastoma [44]. In this model, CitK knockdown leads to cytokinesis defects and G2/M arrest, as expected, but also to apoptosis, DNA damages and senescence [44]. CitK depletion was initially reported to induce apoptosis in a p53-dependent manner, since p53 depletion partially rescued the phenotype [17], but in medulloblastoma, apoptosis was found to rely on both TP53 and TP73 [44]. This information is an important point to consider in the context of cancer, in which TP53 is the most commonly mutated gene, with mutation frequencies reaching 50% in 20 cancer types [88]. Therefore, even in p53-mutated tumors, CitK targeting could still induce apoptosis via a TP73-dependent mechanism, and hence be effective on a large panel of tumors. In cells of other types of cancers investigated, such as bladder cancer [74,83], esophageal squamous cell carcinoma [87] or myeloma [82], the knockdown of CitK also caused multinucleation, G2/M arrest and apoptosis (Table 1). Overall, CitK appears to be a relevant target in a wide variety of cancer models, underscoring its importance for cell division in general [39]. Notably, in addition to causing proliferation defects and apoptosis, CitK depletion also leads to an accumulation of DNA damages [17], which in the context of cancer has only been documented in medulloblastoma so far. Importantly, these DNA damages sensitized medulloblastoma cells to ionizing radiations [32,44]. Thus, it would be interesting to investigate the effect of CitK depletion on the induction of DNA damage and its ability to potentialize ionizing radiation treatment in other cancer types, which could be particularly valuable in a therapeutic context. In vivo experiments The importance of CitK in cancer was confirmed in vivo in the different models listed above (Table 1). Most of the time, CitK-depleted cells were directly implanted in mice. To name just a few, in hepatocellular carcinoma, the size of tumors was decreased when compared to control cells expressing CitK, as well as in breast cancer, myeloma or prostate cancer. More interestingly in medulloblastoma, a conditional knockout mouse model of CitK was developed, leading to decreased tumor size and causing tumor cell apoptosis and senescence [44]. In this model, DNA damages are also observed confirming the role of CitK in this process [44]. These results are encouraging and provided the first evidence of the direct relevance of targeting CitK in cancer using a conditional knockout mouse model. Altogether, this evidence suggests that targeting CitK in cancers could be beneficial. Nevertheless, all the studies described above, except in medulloblastoma [44], rely on experiments based on the implantation of CitK-depleted cells to compare tumor growth in vivo, leading to the conclusion that CitK sustained tumor growth. However, these studies do not allow concluding on the effect of directly targeting CitK in cancer cells due to the lack of specific CitK inhibitors. Potential of inhibiting CitK in cancers Unlike most other kinases, CitK has been rather neglected as a potential therapeutic target, and no specific CitK inhibitors are available yet. However, kinase inhibitors are rarely selective for a single kinase, and with this idea in mind, Davis et al. (2011) conducted an interaction screen between 72 kinases and 442 kinases inhibitors and subsequently, Klaeger et al. (2017) analyzed the targets of 243 kinases inhibitors [89,90]. CitK was among the kinases screened, and these studies identified two kinase inhibitors, Lestaurtinib and OTS167, that show high-affinity binding to CitK, with dissociation constants (Kd) of 85 nM and 98 nM, respectively [89,90]. Lestaurtinib (CEP-701, CAS# 111,358-88–4) was described in 2002 as an Fms-Like Tyrosine kinase 3 (FLT3) and Janus Kinase 2 (JAK2) inhibitor, and OTS167 (CAS# 1,431,697-89–0) in 2012 as a Maternal Embryonic Leucine zipper Kinase (MELK) inhibitor [91–93]. Interestingly, these two inhibitors induce G2/M arrest, cytokinesis defects, apoptosis, and DNA damages in different types of cancers, such as lymphoma [94] or thyroid cancer [95]. However, it turns out that the effects induced by these inhibitors were JAK2-independent for Lestaurtinib [95] and MELK-independent for OTS-167 [96], suggesting that the phenotypes were induced via the inhibition of others targets. Thereafter, the ability of Lestaurtinib and OTS167 to inhibit CitK was described by two different teams, with IC50s of 90 nM and 10 nM 31, 88, respectively. The phenotypes observed following CitK inhibition or depletion are similar to those described for these inhibitors, suggesting that CitK may, at least in part, be the target responsible for these phenotypes. Nevertheless, it is important to keep in mind that these two inhibitors are multi-target inhibitors and that all the effects observed cannot be solely attributed to CitK inhibition. However, it has been shown that Lestaurtinib has no effect on cell proliferation following CitK knockdown (siRNA) and that re-expressing CitK in Lestaurtinib-treated cells rescues the anti-proliferative effect of Lestaurtinib [31]. In addition, the decrease in cell viability observed after OTS-167 treatment was also rescued by CitK overexpression [85]. These results confirm that CitK is indeed targeted by these two drugs and responsible for some phenotypes previously described, which is quite encouraging since no others CitK inhibitors are known. Importantly, CitK inhibition in mice using Lestaurtinib in a medulloblastoma model or OTS167 in a prostate cancer model showed beneficial effects [31,85]. Since Lestaurtinib and OTS-167 have already been tested in phase I or phase II clinical trials for other pathologies [97–99], the tolerance and toxicity of these molecules are known, which could accelerate their repositioning in the clinic in the context of cancer. Furthermore, in the studies by Davis et al. (2011) and Klaeger et al. (2017), other molecules were found to bind to CitK in the low‑nM range and could represent new potent CitK inhibitors [89,90]. For example, CHIR-265 (CAS# 927,880-90–8) binds to CitK with a Kd of 87 nM90, TG-100572 (CAS# 867,334-05–2) with a Kd of 3 nM91, and Y-39983 (CAS# 173,897-44–4) with a Kd of 33 nM91. Interestingly, Y-39983 is a Rho-Associated kinases (ROCK) inhibitor [100], and the kinase domain of CitK shares 50% of homology with ROCK [13]. It is therefore conceivable that this inhibitor may also potently inhibit CitK. It will be interesting to validate the inhibition of CitK with these molecules, and the identification of potent CitK inhibitors will allow confirming whether CitK may constitute a valuable target for cancer treatment. Conclusion Since its identification over 30 y ago, CitK has now a well-established role in mitosis, especially during cytokinesis. However, emerging evidence also points toward a role in interphase, and elucidating these non-mitotic functions will require further investigations. For instance, it is still unclear whether CitK directly regulates the DNA damage response or its implication in cytoskeleton dynamics. It is obvious that its functions remain largely unexplored, especially considering its large web of binding partners. In addition, a single substrate is known so far, and identifying new substrates will be instrumental to better understand its function. In a pathogenic context, a number studies performed over the past 10 y have clearly shown the relevance of CitK in cancer. In conclusion, we are truly believed that CitK is a fascinating kinase that deserves more attention. Supplementary Material Supplementary Table 1.docx Supplementary Table 2.docx Suppl Fig 1.tif Acknowledgements EM was supported by a PhD studentship from the Ministère de l’Enseignement Supérieur et de la Recherche. This work was supported by an FRM Equipes grant (EQU202103012639) from the Fondation pour la Recherche Médicale to AB. Funding Statement The work was supported by the Fondation pour la Recherche Médicale [EQU202403018042]. Disclosure statement No potential conflict of interest was reported by the author(s). The authors report generative AI was not used in their research or preparation of this manuscript. Data availability statement The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials. Supplementary material Supplemental data for this article can be accessed online at https://doi.org/10.1080/15384101.2026.2729549 References Associated Data Supplementary Materials Supplementary Table 1.docx Supplementary Table 2.docx Suppl Fig 1.tif Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.